36772-98-2

Basic information

• Product Name: 2,6-Dibromo-4-acetylresorcinol
• Synonyms: 2,6-Dibromo-4-acetylresorcinol;3',5'-Dibromo-2',4'-dihydroxyacetophenone
• CAS NO: 36772-98-2
• Molecular Formula: C₈H₆Br₂O₃
• Molecular Weight: 309.94
• Mol File: 36772-98-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 174°C
• Appearance: /
• CAS DataBase Reference: 2,6-Dibromo-4-acetylresorcinol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dibromo-4-acetylresorcinol(36772-98-2)
• EPA Substance Registry System: 2,6-Dibromo-4-acetylresorcinol(36772-98-2)

Safety Data

• Hazardous Substances Data: 36772-98-2(Hazardous Substances Data)

Usage

Preparation

Preparation by bromination of resacetophenone in acetic acid.

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 7402-45-1 α,α,α-tribromoacetophenone 
• 56923-41-2 bis-(5-acetyl-2,4-dihydroxy-phenyl)-sulfide 
• 855938-10-2 bis-(5-acetyl-3-bromo-2,4-dihydroxy-phenyl)-sulfide 
• 108-46-3 recorcinol 

Downstream Products

• 672938-16-8 7-acetoxy-6,8-dibromo-4-methyl-3-phenyl-coumarin 
• 126521-72-0 2,4-dibromo-6-ethylresorcinol 
• 873403-43-1 6,8-dibromo-7-hydroxy-4-methyl-3-phenyl-coumarin 
• 850398-70-8 1-(3-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-72-0 1-(5-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 850398-71-9 1-(3,5-bis-ethylsulfanyl-2,4-dihydroxy-phenyl)-ethanone 
• 1351163-30-8 C₁₅H₉Br₂ClO₃ 
• 1351163-28-4 C₁₈H₁₆Br₂O₆ 
• 1351163-29-5 C₁₅H₁₀Br₂O₄ 
• 1351163-32-0 C₁₆H₁₂Br₂O₄ 
• 1351163-31-9 C₁₇H₁₄Br₂O₅ 
• 1257525-68-0 1-(2',4'-dihydroxy-3',5'-dibromophenyl)-3-(3,4-methylenedioxyphenyl)-2-propen-1-one 
• 1311375-72-0 3-(2',4'-dihydroxy-3',5'-dibromophenyl)-5-(3,4-methylenedioxyphenyl)-2-pyrazoline 
• 1311375-80-0 3-(2',4'-dihydroxy-3',5'-dibromophenyl)-5-(3,4-methylenedioxyphenyl)-N-acetylpyrazoline 

Relevant articles and documents

Benzonate derivatives of acetophenone as potent α-glucosidase inhibitors: synthesis, structure–activity relationship and mechanism

In this article, 23 compounds (6 and 7a–7v) were prepared and evaluated for their in vitro α-glucosidase inhibitory activity. The compounds 7d, 7f, 7i, 7n, 7o, 7r, 7s, 7u, and 7v displayed the α-glucosidase inhibition activity with IC50 values ranging from 1.68 to 7.88 μM. Among all tested compounds, 7u was found to be the most efficient, being 32-fold more active than the standard drug acarbose, which significantly attenuated postprandial blood glucose in mice. In addition, the compound 7u also induced the fluorescence quenching and conformational changes of enzyme, by forming α-glucosidase–7u complex in a mixed inhibition type. The thermodynamic constants recognised the interaction between 7u and α-glucosidase and was an enthalpy-driven spontaneous exothermic reaction. The synchronous fluorescence and CD spectra also indicate that the compound 7u changed the enzyme conformation. The findings identify the binding interactions between new ligands and α-glucosidase and reveal the compound 7u as a potent α-glucosidase inhibitor.

The synthesis and synergistic antifungal effects of chalcones against drug resistant Candida albicans

To identify effective and low toxicity synergistic antifungal compounds, 24 derivatives of chalcone were synthesized to restore the effectiveness of fluconazole against fluconazole-resistant Candida albicans. The minimal inhibitory concentration (MIC80) and the fractional inhibitory concentration index (FICI) of the antifungal synergist fluconazole were measured against fluconazole-resistant Candida albicans. This was done via methods established by the clinical and laboratory standards institute (CLSI). Of the synthesized compounds, 2′-hydroxy-4′-methoxychalcone (8) exhibited the most potent in vitro (FICI = 0.007) effects. The structure activity relationship of the compounds are then discussed.

Fibrinogen receptor antagonists and their use

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein the symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.